MetaCap

Amgen (AMGN) vs Neurocrine Biosciences (NBIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amgen (AMGN) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 29.1% versus a gain of 6.2%. Over five years, AMGN leads with a +116.6% price change compared with +73.1% for NBIX. Amgen is the larger company by market cap ($235.64 billion vs $15.24 billion), about 15.5 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +10.0%).

On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.2x vs 17.3x for Amgen). Amgen pays a dividend yielding 2.28%, while Neurocrine Biosciences does not currently pay one. Amgen converts more of its revenue into profit, with a net margin of 21.0% versus 16.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMGN+29.06%NBIX+6.16%
+45%+14%-16%
Nov 21, 20251 yearNov 20, 2026
AMGN+111.39%NBIX+75.04%
+133%+57%-20%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMGN versus NBIX key metrics
MetricAMGNNBIX
Share price$435.64$150.57
Market cap$235.64B$15.24B
1-day change-0.15%-3.84%
YTD return+33.10%+6.16%
1-year return+29.06%+6.16%
5-year return+116.64%+73.11%
P/E ratio (TTM)25.2522.34
Forward P/E17.3412.24
EPS (TTM)$17.25$6.74
Dividend yield2.28%0.00%
Annual dividend$9.94$0.00
Revenue (latest FY)$36.75B$2.86B
Revenue growth (YoY)+9.95%+21.45%
Net income (latest FY)$7.71B$478.60M
Gross margin67.25%98.18%
Operating margin24.71%21.64%
Net margin20.98%16.73%
52-week high$483.99$186.12
52-week low$312.39$122.14
Distance from 52-week high-9.99%-19.10%
Analyst consensusholdstrong_buy
Avg. price target upside-0.88%+38.50%
Average volume2.82M1.34M
Shares outstanding540.91M101.22M
Employees31,5002,500
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Amgen is about 15.5 times larger than Neurocrine Biosciences by market value ($235.64B vs $15.24B).
  • AMGN has outperformed NBIX by 22.9 percentage points over the past year.
  • Amgen offers a meaningfully higher dividend yield (2.28% vs 0.00%).
  • Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +9.95%).

About Amgen

AMGN stock →

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees

About Neurocrine Biosciences

NBIX stock →

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees

AMGN vs NBIX FAQ

Which is bigger, Amgen or Neurocrine Biosciences?

Amgen (AMGN) is larger, with a market capitalization of $235.64B compared with $15.24B for Neurocrine Biosciences (NBIX).

Which stock has performed better over the past year, AMGN or NBIX?

AMGN returned +29.06% over the past 12 months, compared with +6.16% for NBIX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AMGN or NBIX?

NBIX has the lower trailing P/E at 22.3, versus 25.3 for AMGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Amgen or Neurocrine Biosciences?

Amgen pays a dividend yielding 2.28%, while Neurocrine Biosciences does not currently pay a regular dividend.

Are Amgen and Neurocrine Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons